gemfibrozil has been researched along with repaglinide in 19 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (31.58) | 29.6817 |
| 2010's | 13 (68.42) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Backman, JT; Neuvonen, M; Neuvonen, PJ; Niemi, M | 1 |
| Backman, JT; Kajosaari, LI; Laitila, J; Neuvonen, PJ | 1 |
| Backman, JT; Kalliokoski, A; Laitila, J; Neuvonen, M; Neuvonen, PJ; Niemi, M; Tornio, A | 1 |
| Akeson, J; Belknap, SM; Brooks, I; Deitrick, DL; Getz, M; Lanzotti, SA; Maurer, T; Moore, H; Peterson, A; Soltysik, RC; Storm, GA; Yarnold, PR | 1 |
| Backman, JT; Kalliokoski, A; Kurkinen, KJ; Neuvonen, PJ; Niemi, M | 1 |
| Backman, JT; Honkalammi, J; Kurkinen, KJ; Neuvonen, M; Neuvonen, PJ; Niemi, M; Tornio, A | 1 |
| Bode, C | 1 |
| Chen, W; Gan, J; Gao, L; Hong, Y; Humphreys, WG; Li, W; Rodrigues, AD; Shen, H; Tang, Y; Tian, Y; Zhang, H; Zhang, Y | 1 |
| Backman, JT; Honkalammi, J; Neuvonen, PJ; Niemi, M | 3 |
| Hisaka, A; Ito, K; Kudo, T; Sugiyama, Y | 1 |
| Beil, W; Holstein, A; Kovacs, P | 1 |
| El-Kattan, AF; Goosen, TC; Kimoto, E; Kumar, V; Lai, Y; Varma, MV | 1 |
| Kim, SJ; Sugiyama, Y; Toshimoto, K; Yao, Y; Yoshikado, T | 1 |
| Achour, B; Backman, JT; Darwich, AS; Doki, K; Rostami-Hodjegan, A; Tornio, A | 1 |
3 review(s) available for gemfibrozil and repaglinide
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
The nasty surprise of a complex drug-drug interaction.
Topics: Carbamates; Drug Approval; Drug Evaluation, Preclinical; Drug Industry; Drug Interactions; Drug Therapy, Combination; Gemfibrozil; Humans; Itraconazole; Models, Biological; Piperidines | 2010 |
CYP2C metabolism of oral antidiabetic drugs--impact on pharmacokinetics, drug interactions and pharmacogenetic aspects.
Topics: Administration, Oral; Benzamides; Blood Glucose; Carbamates; Cytochrome P-450 Enzyme System; Drug Interactions; Gemfibrozil; Humans; Hypoglycemic Agents; Inactivation, Metabolic; Pharmacogenetics; Piperidines; Polymorphism, Single Nucleotide; Sulfonylurea Compounds; Thiazolidinediones | 2012 |
7 trial(s) available for gemfibrozil and repaglinide
| Article | Year |
|---|---|
Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics and pharmacodynamics of repaglinide: potentially hazardous interaction between gemfibrozil and repaglinide.
Topics: Adult; Antifungal Agents; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Biotransformation; Blood Glucose; C-Peptide; Carbamates; Cross-Over Studies; Cytochrome P-450 CYP2C8; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Drug Interactions; Female; Gemfibrozil; Half-Life; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Insulin; Itraconazole; Male; Piperidines | 2003 |
The effect of gemfibrozil on repaglinide pharmacokinetics persists for at least 12 h after the dose: evidence for mechanism-based inhibition of CYP2C8 in vivo.
Topics: Adult; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Blood Glucose; Carbamates; Cytochrome P-450 CYP2C8; Drug Interactions; Female; Gemfibrozil; Glucuronates; Half-Life; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Male; Piperidines | 2008 |
Effects of gemfibrozil and atorvastatin on the pharmacokinetics of repaglinide in relation to SLCO1B1 polymorphism.
Topics: Administration, Oral; Adult; Area Under Curve; Atorvastatin; Blood Glucose; Carbamates; Cross-Over Studies; Drug Interactions; Female; Gemfibrozil; Genotype; Half-Life; Heptanoic Acids; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Liver-Specific Organic Anion Transporter 1; Male; Organic Anion Transporters; Piperidines; Polymorphism, Genetic; Pyrroles | 2008 |
CYP2C8 activity recovers within 96 hours after gemfibrozil dosing: estimation of CYP2C8 half-life using repaglinide as an in vivo probe.
Topics: Administration, Oral; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Biotransformation; Blood Glucose; Carbamates; Cross-Over Studies; Cytochrome P-450 CYP2C8; Drug Interactions; Enzyme Inhibitors; Female; Gemfibrozil; Genotype; Glucuronates; Half-Life; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Liver-Specific Organic Anion Transporter 1; Male; Models, Biological; Molecular Probes; Organic Anion Transporters; Phenotype; Piperidines; Young Adult | 2009 |
Mechanism-based inactivation of CYP2C8 by gemfibrozil occurs rapidly in humans.
Topics: Adult; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Carbamates; Cross-Over Studies; Cytochrome P-450 CYP2C8; Female; Gemfibrozil; Glucuronates; Humans; Hypoglycemic Agents; Male; Piperidines; Time Factors | 2011 |
Dose-dependent interaction between gemfibrozil and repaglinide in humans: strong inhibition of CYP2C8 with subtherapeutic gemfibrozil doses.
Topics: Adult; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Blood Glucose; Carbamates; Cross-Over Studies; Cytochrome P-450 CYP2C8; Dose-Response Relationship, Drug; Double-Blind Method; Drug Interactions; Female; Gemfibrozil; Genotype; Humans; Male; Organic Anion Transporters; Piperidines; Young Adult | 2011 |
Gemfibrozil is a strong inactivator of CYP2C8 in very small multiple doses.
Topics: Area Under Curve; Aryl Hydrocarbon Hydroxylases; Blood Glucose; Carbamates; Cross-Over Studies; Cytochrome P-450 CYP2C8; Dose-Response Relationship, Drug; Enzyme Inhibitors; Gemfibrozil; Genotype; Glucuronides; Humans; Liver-Specific Organic Anion Transporter 1; Organic Anion Transporters; Piperidines | 2012 |
9 other study(ies) available for gemfibrozil and repaglinide
| Article | Year |
|---|---|
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Metabolism of repaglinide by CYP2C8 and CYP3A4 in vitro: effect of fibrates and rifampicin.
Topics: Aryl Hydrocarbon Hydroxylases; Bezafibrate; Carbamates; Cytochrome P-450 CYP2C8; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Interactions; Fenofibrate; Gemfibrozil; Humans; Hypoglycemic Agents; In Vitro Techniques; Itraconazole; Microsomes, Liver; Midazolam; Paclitaxel; Piperidines; Quercetin; Rifampin | 2005 |
Application of software design principles and debugging methods to an analgesia prescription reduces risk of severe injury from medical use of opioids.
Topics: Adult; Aged; Analgesia, Patient-Controlled; Analgesics, Opioid; Blood Glucose; Carbamates; Clinical Trials as Topic; Drug Interactions; Female; Gemfibrozil; Hospital Mortality; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Male; Medication Errors; Middle Aged; Multicenter Studies as Topic; Pain; Patient-Centered Care; Piperidines; Software | 2008 |
Repaglinide-gemfibrozil drug interaction: inhibition of repaglinide glucuronidation as a potential additional contributing mechanism.
Topics: Biotransformation; Carbamates; Cells, Cultured; Dose-Response Relationship, Drug; Drug Interactions; Gemfibrozil; Glucuronides; Glucuronosyltransferase; Hepatocytes; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Itraconazole; Microsomes, Liver; Piperidines | 2010 |
Analysis of the repaglinide concentration increase produced by gemfibrozil and itraconazole based on the inhibition of the hepatic uptake transporter and metabolic enzymes.
Topics: Area Under Curve; Aryl Hydrocarbon Hydroxylases; Biotransformation; Carbamates; Computer Simulation; Cytochrome P-450 CYP2C8; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Enzyme Inhibitors; Gemfibrozil; Glucuronides; Humans; Hypoglycemic Agents; Itraconazole; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Biological; Nonlinear Dynamics; Organic Anion Transporters; Piperidines | 2013 |
Mechanistic modeling to predict the transporter- and enzyme-mediated drug-drug interactions of repaglinide.
Topics: Aryl Hydrocarbon Hydroxylases; Biological Transport, Active; Carbamates; Cell Line; Cytochrome P-450 CYP2C8; Drug Interactions; Gemfibrozil; Hepatocytes; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Liver-Specific Organic Anion Transporter 1; Models, Biological; Organic Anion Transporters; Piperidines | 2013 |
Quantitative Analysis of Complex Drug-Drug Interactions Between Repaglinide and Cyclosporin A/Gemfibrozil Using Physiologically Based Pharmacokinetic Models With In Vitro Transporter/Enzyme Inhibition Data.
Topics: Biological Transport; Carbamates; Computer Simulation; Cyclosporine; Cytochrome P-450 CYP2C8; Cytochrome P-450 CYP2C8 Inhibitors; Cytochrome P-450 CYP3A; Drug Interactions; Enzyme Inhibitors; Gemfibrozil; Humans; Hypoglycemic Agents; Liver-Specific Organic Anion Transporter 1; Models, Biological; Piperidines | 2017 |
Implications of intercorrelation between hepatic CYP3A4-CYP2C8 enzymes for the evaluation of drug-drug interactions: a case study with repaglinide.
Topics: Adult; Carbamates; Clinical Trials as Topic; Computer Simulation; Cytochrome P-450 CYP2C8; Cytochrome P-450 CYP2C8 Inhibitors; Cytochrome P-450 CYP3A; Drug Interactions; Female; Gemfibrozil; Humans; Hypoglycemic Agents; Male; Microsomes, Liver; Models, Biological; Piperidines; Young Adult | 2018 |